QR код

A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach

<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on human metab...

Повний опис

Збережено в:
Автори: Randh AlAhmari, Hana M. A. Fakhoury, Reem AlMalki, Hatouf H. Sukkarieh, Lina Dahabiyeh, Tawfiq Arafat, Anas M. Abdel Rahman
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2025-08-01
Серія:Pharmaceuticals
Предмети:
Sacubitril/Valsartan
metabolomics
LC-QToF HRMS
pyrimidine metabolism
pharmacokinetics
uridine triphosphate
Онлайн доступ:https://www.mdpi.com/1424-8247/18/9/1264
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси